The financials
Dexcom by the numbers
Dexcom (DXCM) reported revenue of $1.31B in Q2 2026 (quarter ended June 30, 2026), up 13% from the same quarter a year earlier. That came with a gross margin of 63% and net income of $249M (19% of revenue). For the full year FY2025, revenue was $4.66B (+16% year on year) and net income $836M. Its largest region in 2026-Q2 was United States at $894M, 81% of the disclosed total, just ahead of Non Us at 19%.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $1.31B | $1.16B | +13% |
| Gross profit | $830M | $689M | +20% |
| Operating income | $318M | $213M | +50% |
| Net income | $249M | $180M | +39% |
| Diluted EPS | $0.64 | $0.45 | +42% |
| Geographic | Revenue | Share |
|---|---|---|
| United States | $894M | 81% |
| Non Us | $209M | 19% |
Business Segments
Revenue split by geographic segment, from SEC XBRL filings.
Latest period: Q2 2026Total $1.10B (+9.1%)
Non Us grew +17% year on yearUnited States +12% year on year
Segment Latestquarter on quarteryear on year
- United States$893.5M$893.5MQoQ +12%year on year +12%+12%+12%
- Non Us$208.9M$208.9MQoQ -2.1%year on year +17%-2.1%+17%
Medical Devices
Ranks #12 of 35 by Smart Score